The cellular mechanism by which apolipoprotein E (apoE) affects the pathogenesis of Alzheimer's disease (AD) is not understood. We have examined the effect of apolipoprotein E on the internalization of exogenous amyloid-b 1-40 (Ab40) into a rat brain crude synaptosomal preparation. Ab40 peptide in soluble (within 1 h of dilution in buffer) or aggregated (aged 4 days before dilution in buffer) form was pre-incubated with lipidated apoE then added to synaptosomes; intraterminal amyloid-b labeling was quantified using flow cytometry following immunolabeling with the anti-Ab (10G4) antibody. The number of Ab-positive synaptosomes was increased (50%) by treatment with a soluble Ab/apoE mixture compared with treatment with soluble Ab40 alone. However, when the Ab was aggregated, less sodium dodecyl sulfate (SDS)-stable Ab/apoE complex was formed and the addition of apoE decreased the number of Ab-positive terminals. The addition of the lipoprotein-receptor related protein (LRP) antagonist receptor-associated protein (RAP) inhibited the apoE-induced increase in synaptosomal Ab, and controls treated with trypsin and heparinase confirm intraterminal localization of the majority of the soluble Ab. The apoE-mediated increase in Ab labeling was confirmed in intact cells by immunocytochemistry of dorsal root ganglion (DRG) neurons. These results suggest that complex formation with apoE enhances internalization of soluble Ab uptake into terminals.
Much evidence supports the in vitro and in vivo neurotoxicity of amyloid-b, a peptide whose progressive self-aggregation in solution is well documented, and fibrillar amyloid-b protein (Ab) results in increased cellular toxicity (Pike et al. 1991a (Pike et al. , 1993 Lorenzo and Yankner 1994) . The longer, more fibrillogenic 1-42 peptide is more abundant in Alzheimer's disease (AD) brain than in controls (Roher et al. 1993) , and presenilin mutations that result in early onset AD increase production of 1-42 peptide (Scheuner et al. 1996) . These findings have led to an amyloid cascade hypothesis in which seeding of insoluble Ab42 represents the initiating event in plaque development (Selkoe 1999) . However, amyloid plaques may be distant from sites of synaptic and neuron loss, and loss of synaptic terminals in AD brains demonstrates a higher correlation with loss of cognitive function than other pathological markers such as cell death or plaque formation (Masliah et al. 1994; Terry 1999) . Likewise, transgenic mouse models have previously shown a weak correlation between amyloid load and memory/cognitive function (Terry 1999; Klein et al. 2001) . For example, in transgenic mouse models, overexpressing mutant or wildtype hu-APP, synapse loss correlated with soluble Ab level rather than amyloid-b precursor protein (APP) level or amyloid deposits, i.e. synapse loss occurred even when amyloid was not deposited (Mucke et al. 2000) .
Recent evidence suggests that soluble Ab forms, particularly protofibrils and small oligomers, are potent neurotoxins that may play an important role in early pathogenesis and synapse loss (Lambert et al. 1998) . Observations in post-mortem human studies also support the notion that soluble Ab forms may make a previously unrecognized contribution to early synaptotoxicity in AD (Klein et al. 2001) . For example, the more soluble 1-40 Ab peptide correlates better than the 1-42 species with disease severity (McLean et al. 1999) , and with apolipoprotein E (apoE) 4 dosage in late onset AD (Ishii et al. 1997) , and Ab40 level is a stronger predictor of synaptic changes (Funato et al. 1998; Lue et al. 1999) .
To date, inheritance of the apoE4 allele is the major genetic factor associated with the common late-onset form of AD (Corder et al. 1993) , and possession of one or two apoE2 alleles seems to serve a protective function (Corder et al. 1994) . Transgenic studies have shown that, in mice overexpressing human APP with zero, one or two apoE genes, amyloid deposits are markedly reduced in apoE-negative mice (Bales et al. 1999) . The simplest explanation for a contribution of apoE4 to AD development is a direct interaction between apoE and Ab protein, and one compelling hypothesis has been that apoE-bound Ab is a ligand for the multifunctional low-density lipoprotein-related protein (LRP) receptor: uptake of Ab/apoE complex by LRP receptor may then be a mechanism of Ab clearance from the neuropil (Rebeck et al. 1995) . With the objective of clarifying how Ab internalization is affected by apoE, the studies reported here used a rat brain crude synaptosomal preparation as a model system for the study of Ab accumulation in nerve terminals. We have examined the effects of exogenously applied apolipoprotein E in combination with soluble and aggregated forms of Ab40 peptide, and quantified terminal-associated Ab labeling using flow cytometry analysis.
Materials and methods

Materials
Recombinant human apoE3 was purchased from Panvera (Madison, WI, USA), and b-amyloid (1-40) was purchased from Anaspec, Inc. (San Jose, CA, USA). Phycoerythrin-conjugated anti-mouse IgG was purchased from Molecular Probes (San Diego, CA, USA). Receptor-associated protein (RAP) was kindly provided by G. Bu (University of Washington University School of Medicine, St Louis, MO, USA). Polystyrene microsphere size standards were purchased from Polysciences, Inc. (Warrington, PA, USA). Dimyristoylphosphatidylcholine (DMPC), heparinase, and other reagents were purchased from Sigma (St Louis, MO, USA).
P-2 preparation
The P-2 (crude synaptosome) fraction was prepared as described previously (Weiler et al. 1981) ; briefly, adult male Sprague Dawley rats were decapitated and brains (minus cerebellum) were rapidly removed and placed in 10 volumes of ice cold 0.32 M sucrose in 10 mM Tris buffer (pH 7.4) with protease inhibitors (2 mM EGTA, 2 mM EDTA, 0.2 mM phenylmethylsulfonyl fluoride (PMSF), 4 lg/mL leupeptin, 4 lg/mL pepstatin, 5 lg/mL aprotinin, 20 lg/mL trypsin I). The tissue was homogenized in a Teflon/glass homogenizer (clearance 0.1-0.15 mm) by eight gentle up and down strokes at 800 rpm (Setting 1.5; Tri-R Instruments Model K-41, Rockville Center, NY, USA). The homogenate was spun at 1000 g for 10 min to remove nuclei and cell debris. The resulting supernatant was centrifuged at 10 000 g for 20 min to obtain the crude synaptosomal pellet. The final pellet was washed with 2 mLs of Krebs-Ringer phosphate buffer [KRP; 118 mM NaCl, 5 mM KCl, 4 mM MgSO 4 , 1 mM CaCl 2 , 1 mM KH 2 PO 4 , 16 mM sodium phosphate buffer (KRP; pH 7.4), and 10 mM glucose] and centrifuged (4 min, 2000 g, 4°C) before resuspension in KRP for incubations.
Preparation of amyloid-b/apoE complex For all experiments, apoE was first relipidated with dimyristoylphosphatidylcholine (DMPC) using a procedure modified from Innerarity et al. (1986) . Briefly, hydrated DMPC was sonicated for 1 h then filtered (0.2 lm). ApoE was solubilized in 4 mM HEPES, added to sonicated DMPC, and then cycled through the transition temperature three times by warming to 30°C and cooling to 15°C in a thermocycler (Perkin Elmer GeneAmp, Foster City, CA, USA). This lipidated apoE mixture was immediately added to Ab solutions and incubated at 37°C for 30 min to allow complex formation prior to addition to synaptosomal preparations.
Soluble Ab
Lyophilized peptides were solubilized in deionized water (230 lM) and stored in aliquots at )80°C until dilution in KRP buffer immediately prior to experiments.
Aged Ab
Peptide aliquots were diluted 1 : 1 in 2 · phosphate-buffered saline (PBS) and incubated in a capped vial at 37°C for 4 days before use (Pike et al. 1993) .
Treatment and immunolabeling of P-2 fraction Aliquots of P-2 homogenate were incubated with Ab or Ab/apoE (5.6 lM and 1 lM, respectively) in KRP buffer for the time indicated in a 32°C water bath with intermittent agitation. Treated P-2 aliquots were immunolabeled for flow cytometry analysis according to a method for staining of intracellular antigens (Schmid et al. 1991) . Pellets were fixed in 0.25% buffered paraformaldehyde (1 h, 4°C) and permeabilized in 0.2% Tween20/PBS (15 min, 37°C). The monoclonal antibody 10G4 (Yang et al. 1994 ) (raised against Ab1-40 and mapping to residues 5-13), was diluted 1 : 1000 in 2% fetal bovine serum (FBS)/PBS. Following a 30-min incubation with primary antibody at 4°C, pellets were washed two times with 1 mL 0.2% Tween20/PBS, then incubated (20 min, 4°C) with secondary antibody (FITC-conjugated anti-mouse IgG) followed by two additional washes before resuspension in KRP buffer for flow cytometry analysis.
Flow cytometry
Flow cytometry was performed with a FACScan (Becton-Dickinson, Mountain View, CA, USA). Sample flow rate was approximately 3000 events per second; 20 000-50 000 events were collected for analysis. A threshold was set on forward light scatter (channel 42) to exclude debris. Drawing an analysis gate on the largest particles (greater than 1 lm based on size standards) excludes most contaminants and results in focus on the neuronal (SNAP-25-positive) elements in the homogenate, therefore a data analysis gate was drawn to include only the largest particles for each experiment, which are greater than 95% neuronal (SNAP-25-positive; Gylys et al. 2000 Gylys et al. , 2002 . Analysis was performed using FCS Express software (DeNovo software, Ont., Canada). Student's t-test for independent observations and two-way ANOVA procedures were performed using the Vassarstat statistical computation web site.
Western analysis
Aliquots of the Ab/apoE complex mixture (1.08 lg Ab; 1.57 lg apoE) were boiled for 5 min in non-reducing Laemmli buffer [4% sodium dodecyl sulfate (SDS), no b-mercaptoethanol], and loaded onto a 10-20% SDS/Tricine gel. The separated proteins were transferred to Immobilon-P membranes, and probed with the 10G4 antibody to Ab in an overnight incubation (1 : 1000 dilution). Proteins on western blots were visualized by enhanced chemiluminescence (ECL; Amersham Pharmacia Corp., Piscataway, NJ, USA).
Cell culture Dorsal root ganglion (DRG) were cultured from C57BLK mice pups, p 0-1. The ganglia were quickly dissected out, enzymatically digested in trypsin, triturated to create a dissociated cell suspension and then plated onto coverslips coated with poly ornithine and laminin. The cultures were grown in Neurobasal media supplemented with B25, glutamine, penstrep, and fluoro-deoxyuridine to prevent glial proliferation; nerve growth factor was included for the initial 3 days then withheld upon subsequent feedings. On day 7 in vitro (DIV), the cultures were treated with soluble or aggregated Ab peptides, with and without lipidated apoE, for 1 h as described above for synaptosomes. Cells were immunolabeled for Ab with the 10G4 antibody as described above with the following exceptions: the fixation step utilized 4% PBS-buffered paraformaldehyde, and 0.1% Triton X-100 was used for permeabilization. Cells were incubated overnight with primary antibody, and for 2 h with FITCconjugated anti-mouse IgG.
Results
Ab/apoE complex formation is increased with soluble compared with aggregated Ab40 peptide In order to examine how Ab aggregation state affects interactions with apoE, Ab/apoE mixtures were incubated (30 min, 37°C) to allow complex formation using conditions based on the characterization of amyloid-b/apoE interactions by LaDu and colleagues (LaDu et al. 1994 (LaDu et al. , 1997 . Soluble Ab was diluted from frozen aliquots immediately prior to experiments; aggregated Ab was pre-aggregated in a capped vial for 4 days before complex formation with apoE. Electron microscopy and thioflavin-T staining have demonstrated that visible protofibrils and b-sheet structure are not detected in freshly solublized Ab40 peptide (Michikawa et al. 2001) . The biochemical properties and toxicity of aggregated Ab40 under our conditions have also been documented (Pike et al. 1991a,b; Burdick et al. 1992; Pike et al. 1993) . When Ab/apoE mixtures (5.6 and 1 lM, respectively) were analyzed on non-reducing SDS gels, monomeric Ab was observed at 4 kDa, and a 43 kDa band consistent with the SDS-stable Ab/apoE complex observed in previous work was detected with the 10G4 antibody against Ab ( Fig. 1 ; LaDu et al. 1994) . In longer exposures, a small amount of Ab immunoreactivity was observed at the expected position for a Ab/apoE dimer complex (data not shown). Despite equal loading, an apparent decrease in the amount of monomeric Ab in the aggregated condition is visible in Fig. 1 . Consistent with previous evidence that apoE accelerates Ab fibril formation, this discrepancy likely results from insoluble high-molecular weight aggregates in the Ab/apoE mixture that fail to enter the gel and transfer to the filter (Ma et al. 1994; Wisniewski et al. 1994; Golabek et al. 1996) . When Ab peptide was pre-aggregated for 4 days in PBS prior to complex formation with apoE (lane 2), the amount of complex was decreased (nine-fold) compared with the amount formed with freshly solubilized Ab40 (lane 1). These results indicate that Ab pre-aggregation reduces the formation of SDS-stable Ab/apoE complex.
Treatment of synaptosomes with the soluble Ab/apoE combination increases the number of Ab-positive terminals In order to examine the hypothesis that the Ab/apoE complex results in differential uptake of Ab into neurons, we compared the amount of Ab in neuronal terminals following in vitro treatment of synaptosomes with Ab alone or with Ab/apoE mixture. In all experiments, Ab was examined in both soluble and pre-aggregated form; Ab/apoE mixtures were incubated for 30 min immediately prior to synaptosome treatments to allow complex formation. After staining with anti-Ab antibody using a protocol for staining of intracellular antigens, the number of positive particles was quantified using flow cytometry. Figure 2 shows representative density plots of Ab fluorescence versus forward scatter, which is proportional to size. The rectangular data analysis gate is drawn to include only synaptosomes that are specifically immunolabeled with the anti-Ab antibody. The distribution of synaptosomes with non-specific labeling (mIgG; Fig. 2a ) is similar to that of untreated (time 0) synaptosomes positive for Ab labeling (Fig. 2b) . The number of Ab-positive particles is increased following incubation with the Ab/apoE mixture (Fig. 2c) compared with synaptosomes incubated with Ab alone (Fig. 2d) . In contrast to the results with soluble Ab, when the Ab is pre-aggregated, addition of apoE to the mixture does not result in increased Ab labeling compared with the aggregated Ab alone (Fig. 2f) . Because smaller Ab aggregates would be expected to be in the same size range as synaptosomes, we immunolabeled pre-aggregated Ab; Fig. 2(g) illustrates that unbound aggregates do not contribute to the fluorescence measured when tissue is treated with aggregated Ab (Figs 2e and f) . Polystyrene microspheres (Fig. 2h) analyzed with identical cytometer settings show that most synaptosomes are from 0.5 to 1 lm in size, consistent with previous flow cytometry (Wolf and Kapatos 1989) and electron microscopy studies (Nagy and Delgado-Escueta 1984; Dunkley et al. 1986 ). Previous characterization of our flow cytometry assay has shown that virtually all of the large particles (1-4 lm) in the crude preparation represent intact synaptosomes that stain with a neuronal marker (Gylys et al. 2000) .
The magnitude and time course of apoE effects on terminal Ab labeling is illustrated graphically in Fig. 3 for both soluble (Fig. 3a) and aggregated (Fig. 3b) Ab1-40. The number of Ab-positive particles was taken from data analysis gate R2 described above; to avoid potential inclusion of free mitochondria or membrane fragments, particles less than 0.75 lm were eliminated by gating analysis. In all conditions, the percentage of Ab-positive synaptosomes is increased to near maximum levels after a 10-min incubation, revealing rapid kinetics in this preparation for increased intraterminal labeling following addition of exogenous Ab. Figure 3 also reveals that the percentage of Ab-positive particles is higher at all time points for aggregated compared with soluble Ab. The soluble Ab/apoE mixture significantly increased the number of Ab-positive synaptosomes compared with soluble Ab alone (F ¼ 11.66; d.f. 1,14; p < 0.005; two-way ANOVA): after 10 min, the number of amyloid-positive particles increased from 19 (± 2.9) to 29% (± 3.0). The maximum increase, from 20 (± 0.3) to 38% (± 4.6) was observed after 3 h. Figure 3(b) shows that when Ab was in aggregated form, the Ab/apoE mixture decreased the number of Ab-positive terminals compared with aggregated Ab alone (F ¼ 14.84; d.f. 1,10; p < 0.005; two-way ANOVA).
The apoE-mediated increase in terminal labeling of soluble Ab is blocked by RAP To test the hypothesis that the low-density LRP mediates binding and uptake of the Ab/apoE complex, we tested the effect of RAP, an LRP antagonist, on synaptosomal Ab labeling. Figure 4a illustrates that the addition of RAP (1 lM) decreased the number of Ab-positive particles from 21.02 (± 5.5) to 8.43 (± 1.62) for the soluble Ab form when apoE was present, indicating receptor-mediated uptake of the Ab/apoE complex (p < 0.05, student's t-test). RAP did not affect the number of amyloid-positive terminals for soluble Ab alone, and did not result in significant decreases in labeling of aggregated Ab (Fig. 4b) . However, the trend toward a decrease observed when RAP was added to aggregated Ab alone (Fig. 4b) , though not statistically significant (p ¼ 0.20, student's t-test), suggests some blockade of non-specific uptake by RAP. RAP-mediated blockade of aggregated Ab may also indicate the presence of a minor pool of monomer in the aggregated peptide that is able to bind apoE and be taken up by the LRP mechanism. It should be noted that RAP is an antagonist for all ligands of the LRP receptor which include alpha-2 macroglobulin and plasminogen activators in addition to other lipoproteins (Herz et al. 1991; Rebeck et al. 1995) .
Previous reports have suggested that amyloid peptides may interact with heparan sulfate proteoglycans (HSPG) on the cell surface (Ji et al. 1997 (Ji et al. , 1998 . Other studies have shown that Ab1-40 peptide associated with PC12 cells can be removed by trypsin incubation (Burdick et al. 1997) . Because both cell surface and intracellular Ab antigen are detected with the staining procedure used in the present experiments, we examined the effect of trypsin and heparinase on synaptosomal Ab labeling. Ab-treated synaptosomes were incubated with trypsin (1 : 1000) or heparinase (10 U/mL) prior to fixation, permeabilization, and staining. Following treatment with trypsin, 90% of the Ab remains in synaptosomes treated with soluble peptide, and 60% of the amyloid remains in aggregated Ab-treated samples. These results suggest that a portion of aggregated Ab is bound but not internalized, but that the majority of soluble Ab measured by flow cytometry is intraterminal. Figure 4 (c) shows that heparinase does not significantly reduce the percentage of Ab-positive synaptosomes following treatment with either soluble or aggregated peptide, indicating that HSPG may not play an essential role in the association of either form of Ab with terminals.
ApoE enhances immunolabeling of soluble Ab in cultured DRG neurons
To confirm that our preparation of relipidated apoE can increase receptor-mediated Ab uptake into neurons and their terminals, dorsal root ganglion cultures were treated with soluble and aggregated Ab alone and in combination with relipidated apoE; Ab was visualized using an intracellular staining protocol (Fig. 5) . Ab-treated cultures were compared Fig. 2 Flow cytometry assay for Ab40 levels in nerve terminals. Representative density plots of Ab fluorescence versus forward scatter (which is proportional to size). Crude synaptosomes were incubated as described in Materials and methods with the Ab/apoE mixture or with Ab alone at 32°C prior to immunolabeling with an antibody against Ab. The rectangular analysis gate is drawn to exclude non-specific labeling determined by staining with isotypespecific (mouse IgG) control antibody; 10 000 events are plotted. Synaptosomes that are non-specifically labeled are located below the gate. The distribution of background-stained synaptosomes (a) is similar to that of untreated (time 0) synaptosomes stained with the 10G4 antibody (b). The percentage of Ab positive particles is shown for synaptosomes treated with: soluble Ab alone (c), with an Ab/apoE mixture for 3 h (d), and with pre-aggregated Ab alone (e) and with an aggregated Ab/apoE mixture for 3 h (d). The particle distribution with identical instrument settings is shown for for immunolabeled Ab aggregates without tissue (g), and for polystyrene microspheres (h).
with cultures treated with Ab/apoE complex. Cells treated with soluble Ab alone demonstrate minimal staining (Fig. 5b) , but those treated with the soluble Ab/apoE mixture display intense punctate labeling along the neurites consistent with terminal staining and in the perinuclear region within the soma (Fig. 5c ) that is attenuated by the addition of RAP (Fig. 5d) . Aggregates varying in size from < 1 to approximately 10 lm are visible on the glial monolayer in cells treated with aggregated Ab alone (Fig. 5e) . When cells were treated with aggregated Ab/apoE mixture, there appear to be more neuron-associated aggregates compared with cells treated with aggregated Ab alone (Fig. 5f) , and the aggregates appear to be larger. When apoE is present, faint aggregates 1 lm or less (arrowhead, Fig. 5f ), may represent a low level of internalization of small Ab aggregates; the larger aggregates appear extracellular. These results in intact cells parallel our data in terminals showing that Ab/apoE (a) (b) Fig. 3 ApoE3 enhances synaptosomal levels of soluble Ab. Time course for apoE effects on terminal Ab levels for soluble (a) and aggregated (b) Ab40 peptide. Crude synaptosomes were treated as described with the Ab/apoE mixture or with Ab alone; the number of amyloid-positive particles is taken from data analysis gate R2 shown in Fig. 1 . Data are from at least four independent experiments; apoE effect is significant at the 0.005 level by two-way ANOVA. Synaptosomes were first incubated with Ab for 1 h, then with heparinase (10 U/mL) or trypsin (1 : 1000) prior to labeling and flow cytometry analysis of Ab-positive particles as described; the number of amyloid-positive particles is taken from data analysis gate R2 shown in Fig. 1 . Data are from at least four independent experiments; *p £ 0.05 compared with Ab/apoE treatment without RAP.
ApoE enhances soluble Ab uptake 1447 complex increases soluble amyloid-b levels, but it should be noted that the large amyloid aggregates visualized in DRG neurons (Figs 5e and f) are excluded based on their size from the synaptosome studies by the flow cytometry analysis (see Fig. 2 ).
Discussion
Increasing evidence suggests that soluble and oligomeric Ab forms may contribute significantly to early amyloid toxicity in AD, and that synapses are a focal site for early damage. The present experiments examine the initial binding/internalization response of nerve terminals to exogenously applied Ab and compare accumulation of Ab in terminals following soluble versus aggregated Ab peptide treatment and treatment with a mixture of Ab/apoE. The effect of apoE on Ab labeling is quantified in a virtually pure synaptic terminal population from adult mammalian brain. Few studies have examined cellular effects of Ab/ apoE binding interactions, and the present results demonstrate that apoE increases terminal Ab level in a RAP-dependent manner.
Both 1-40 and 1-42 species of the amyloid-b protein are found in AD plaques, but only the Ab40 peptide correlates with apoE4 dosage and disease severity. Based on these and other results, McLean et al. (1999) have suggested that a large relatively static insoluble pool of Ab may be derived from a smaller soluble pool that is constantly turning over. These authors suggest lowering the level of the soluble pool, which may be both intracellular and extracellular, as a therapeutic target. Moreover, high levels of Ab in APP transgenic mice resulted in loss of synaptophysin-positive terminals in the absence of plaques (Mucke et al. 2000) , suggesting that plaque-independent Ab toxicity contributes to early synaptic deficits. Considered with results showing that behavioral impairments, synaptic loss and transmission deficits precede plaque formation in some transgenic AD models (Chapman et al. 1999) , these results emphasize the need to understand mechanisms underlying initial cellular responses to both soluble and aggregated forms of Ab peptides. In vitro studies have shown that apoE binds avidly to Ab peptides, forming SDS-stable complexes (Strittmatter et al. 1993a,b; Wisniewski et al. 1993; LaDu et al. 1994 LaDu et al. , 1997 . Only a small proportion of the total Ab peptide in the binding reaction complexes with apoE (Ladu et al. 1994) , but the stoichiometry of the interaction is not understood, in part because denaturing sodium dodecyl sulfate -polyacrylamide gel electrophoresis (SDS-PAGE) analysis may eliminate physiologically relevant classes of Ab/apoE complex. For example, one study of native complex formation identified Ab bound to apoE tetramer as one of several species of high molecular weight complexes (Chan et al. 1996) . However, the potential importance of SDS-stable complex formation is highlighted by the observation that immunoprecipitaed Ab from plaque-free control brains is bound to apoE in an SDSstable complex (Russo et al. 1998) . The level of Ab/apoE complex was higher in control brains than AD brains, leading these authors to speculate that apoE sequesters Ab and prevents aggregation. The observation that apoE increases the binding of Ab40-lipid particles to primary cultures raises the additional possibility that that cholesterol and phosphatidylcholine may be a part of the complex that is ultimately internalized (Michikawa et al. 2001) . The impaired complex formation by aggregated Ab that we observe seems likely to result from the loss of apoE-binding sites to self-aggregation. This explanation is supported by previous work showing that adjacent sections of the amyloid peptide are involved in apoE binding and self-aggregation: hydrophobic residues at the C-terminus (25-35) underlie self-aggregation and neurotoxicity (Pike et al. 1993) , and residues 13-28 are important for the binding of apoE and Ab (Chan et al. 1996) .
LRP is a multifunctional receptor that binds a number of complex and structurally unrelated ligands (Gliemann 1998) Several of these ligands (including a2 macroglobulin and lactoferrin) have been localized to amyloid plaques in AD, and the apoE4 isotype has been shown to form less SDSstable complex than apoE3 (LaDu et al. 1994) . These and other observations have prompted the hypothesis that normal clearance of apoE-bound Ab via LRP internalization is impaired in AD (LaDu et al. 1994; Rebeck et al. 1995; LaDu et al. 1997 ). In the model outlined by Rebeck et al. (1995) , LRP ligands that fail to be internalized and degraded by the usual clearance pathways become associated with the senile plaque. These authors speculated that, for apoE, the receptor-binding domain is available for binding to LRP, resulting in binding to the cell surface without internalization. Our results showing enhanced uptake of soluble but not aggregated Ab are predicted by this model, as is the observation that apoE promotes cellular association of Ab aggregates with DRG cells (Figs 5e and f) . The present results indicate that lower levels of ligand-bound complex rather than impaired receptor function may be the cause of impaired internalization. Extracellular accumulation of aggregated Ab resulting from either receptor dysfunction or reduced complex formation might serve as the seed for extracellular plaques.
Discrepencies exist in the literature regarding the cellular location of exogenously applied Ab peptide, and previous work has shown clear cell-specific and peptide-specific differences. For example, oligomeric 1-42 peptide, a potent neurotoxin, is removed from cultured cells by trypsin treatment (Lambert et al. 1998) ; these authors suggest that toxicity does not follow internalization, but follows surface binding followed by activation of Fyn, a tyrosine kinase in the Src family. This is in contrast to PC12 cells, where both 1-40 and 1-42 Ab peptides were internalized; the 1-40 peptide was eliminated by the cells with a half-life of 1 h, while most of the 1-42 peptide accumulated intracellularly Burdick et al. 1997) . Internalization of Ab40 peptide in the presence of apoE has not been examined, although studies in Chinese hamster ovary cells and in primary hippocampal neurons support the hypothesis that apoE increases cellular association of Ab40 peptide (Beffert et al. 1998; Yang et al. 1999) . The significant proportion of both aggregated and soluble Ab labeling that remains in the presence of RAP in synaptosomes, considered together with the avid surface absorption of Ab peptides (Burdick et al. 1997) , and the nonspecific internalization of amyloid-b aggregates by microglia (Paresce et al. 1996) , indicates that both receptor-mediated and non-specific internalization occur in nerve terminals. Therefore the trypsin-insensitive Ab labeling we observe in synaptosomes may represent surface-bound aggregates that are in the process of non-specific internalization by constitutive membrance endocytosis. Without apoE, there are more Ab-positive terminals for aggregated compared with soluble Ab; apoE raises the percentage of Ab-positive terminals obtained with soluble Ab to approximately the level obtained with aggregated Ab alone (30% positive). Saturation of a non-specific mechanism for aggregated Ab might provide an explanation for the absence of an apoE-induced enhancement of aggregated Ab uptake in the present experiments. The size difference between synaptosomes and DRG neurons would be expected to yield differences with respect to internalization of aggregates: the larger aggregates are 5-10 lm, larger than most synaptosomes, which range from several tenths to 4 lm (Gylys et al. 2000) and particles larger than 5 lm are excluded from the flow cytometry analysis. A higher endocytotic rate in the in vitro preparation might also be expected, given previous work showing increased oxidative activity in synaptosomes compared with cells (McKenna et al. 1993) .
In summary, our results demonstrate that addition of apoE increases terminal Ab labeling for soluble but not aggregated Ab1-40 peptide. The blockade of this increase by RAP indicates receptor-mediated internalization of a soluble Ab/ apoE complex, and the model system and flow cytometry method described offer a quantitative and rapid assay for future studies to examine the neuronal effects of additional amyloid peptide species and the three human apoE isoforms.
The present results highlight the importance of the aggregation state of amyloid-b, and suggest that peptide that becomes self-aggregated before internalization remains in the extracellular space, and may be a source of initial amyloid deposition.
